The global acute coronary syndrome market is expected to witness significant growth over the forecast period, driven by rising prevalence of life style associated disorders such as diabetes, rising cholesterol level and obesity. Furthermore, rising incidences of hypertension, growing adoption of drug and smoking abuse are likely to trigger the market growth in coming seven years. Shifting lifestyle complemented with changing food habits is one of the prime reasons for the growth of acute coronary syndrome (ACS) market. ACS is a medical condition resulting due to reduction in blood flow in the arteries. In this condition, heart muscles are not able to function properly and if not treated at the early stage then it may result in heart attack. Supportive medical reimbursement facilities, rising personal disposable income, and improving healthcare infrastructure is likely to propel the ACS market growth over the forecast period. In developed nations incidences of ACS is higher than developing nations but the mortality associated with ACS in developing nations is higher than developed economies. Early stage disease diagnosis and affordable medical treatments can be possible reason for low mortality in developed nations.
The ACS market is segmented on the basis of drugs and types. The global acute coronary syndrome market is studied under three main types namely; ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA). When body suffers from shortage of blood flow and oxygen then chances of unstable angina occurrence increases which may leads to heart attack. NSTEMI generally occurs when the coronary artery is partially blocked by blood clots. STEMI occurs when the coronary artery is fully blocked by clot which may result in death of the patient. By drugs, the market is segmented into antithrombotic, antihypertensive and statin drugs market. Antihypertensive drugs are anticipated to show lucrative growth over the forecast period owing to increasing incidences of high blood pressure, myocardial infarction and stroke.
Geographically, the global ACS market is segmented into North America, Latin America, Europe, Asia Pacific and MEA. In 2014, North America and Europe were the dominant regions. Due to rising awareness about acute coronary syndrome U.S. was the largest market in North America followed by Canada. Asia Pacific region is anticipated to show highest growth rate over the forecast period owing to increasing number of outsourcings in Asian region. Furthermore, increasing disposable income, rising medical tourism and growing awareness about ACS are expected to drive the market over the forecast period.
The major market players are Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Boehringer Ingelheim, Johnsons & Johnsons, Merck, Novartis, Amgen, AbbVie, Portal Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Eli Lilly, Daiichi, Sanofi, Regeneron and Sankyo. Due to the presence of large number of market players, the global acute coronary syndrome market is highly competitive in nature. The firms have to go through many business development activities such as new product development, mergers, collaboration and geographical expansion to sustain in the market.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.